TWI326598B - Unit dosage forms of temozolomide - Google Patents

Unit dosage forms of temozolomide Download PDF

Info

Publication number
TWI326598B
TWI326598B TW096122905A TW96122905A TWI326598B TW I326598 B TWI326598 B TW I326598B TW 096122905 A TW096122905 A TW 096122905A TW 96122905 A TW96122905 A TW 96122905A TW I326598 B TWI326598 B TW I326598B
Authority
TW
Taiwan
Prior art keywords
days
per day
day
patient
day cycle
Prior art date
Application number
TW096122905A
Other languages
English (en)
Chinese (zh)
Other versions
TW200808803A (en
Inventor
Jacqueline Rose Bersch
Mark Manzo
Sumant Ramachandra
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200808803A publication Critical patent/TW200808803A/zh
Application granted granted Critical
Publication of TWI326598B publication Critical patent/TWI326598B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW096122905A 2006-06-26 2007-06-25 Unit dosage forms of temozolomide TWI326598B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26

Publications (2)

Publication Number Publication Date
TW200808803A TW200808803A (en) 2008-02-16
TWI326598B true TWI326598B (en) 2010-07-01

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096122905A TWI326598B (en) 2006-06-26 2007-06-25 Unit dosage forms of temozolomide

Country Status (13)

Country Link
EP (1) EP1901740A2 (no)
JP (1) JP2008534692A (no)
KR (2) KR20100055543A (no)
CN (1) CN101309686A (no)
AR (1) AR061618A1 (no)
AU (1) AU2007221979A1 (no)
BR (1) BRPI0702847A (no)
CA (1) CA2610439A1 (no)
CL (1) CL2007001864A1 (no)
NO (1) NO20074913L (no)
TW (1) TWI326598B (no)
WO (1) WO2008002544A2 (no)
ZA (1) ZA200708280B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
EP3432901B1 (en) * 2016-03-21 2021-09-01 Duke University Sequential anti-cancer treatment
WO2018167627A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE310515T1 (de) * 1999-03-30 2005-12-15 Schering Corp Verbesserte krebsbehandlung mit temozolomid
CA2585446A1 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level

Also Published As

Publication number Publication date
CN101309686A (zh) 2008-11-19
AU2007221979A9 (en) 2008-01-10
AU2007221979A1 (en) 2008-01-10
WO2008002544A2 (en) 2008-01-03
NO20074913L (no) 2009-03-26
ZA200708280B (en) 2009-03-25
EP1901740A2 (en) 2008-03-26
AR061618A1 (es) 2008-09-10
CL2007001864A1 (es) 2008-02-08
CA2610439A1 (en) 2007-12-26
BRPI0702847A (pt) 2008-04-01
WO2008002544A3 (en) 2008-02-07
JP2008534692A (ja) 2008-08-28
KR20100055543A (ko) 2010-05-26
TW200808803A (en) 2008-02-16
KR20080015777A (ko) 2008-02-20

Similar Documents

Publication Publication Date Title
Morrison et al. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer
Plummer et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
EP3984537B1 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
US20060100188A1 (en) Treatment methods
US20120270900A1 (en) Novel method of treatment
EP2409700A1 (en) Methods of treatment using intravenous formulations comprising temozolomide
TW202242144A (zh) Ｗｅｅ１抑制劑及用於治療癌症之方法
US20080090242A1 (en) Panel of biomarkers for prediction of fti efficacy
JP5651125B2 (ja) Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
TWI326598B (en) Unit dosage forms of temozolomide
US20080319039A1 (en) Unit dosage forms of temozolomide
CN115998872A (zh) 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途
WO2013103836A2 (en) Methods of treating cancer
CA3149112A1 (en) Novel therapeutic use
MX2007012093A (en) Unit dosage forms of temozolomide
Metzler et al. Emergence of translocation t (9; 11)‐positive leukemia during treatment of childhood acute lymphoblastic leukemia
KR20240026704A (ko) Ginsenoside Rk1을 포함하는 전립선암 예방 또는 치료용 약학적 조성물
EP4045687A1 (en) Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy